Rahul Banerjee, Assistant Professor at the Fred Hutchinson Cancer Center and at the University of Washington, shared posts on X:
“EHA 2026 a new standard of care about to emerge in myeloma!
Plasma Cell Pete looking as presidential as ever at the plenary session MonumenTAL-3: tal-dara +/- pom versus Dara-Pd. Tal-DP and tal-D both dramatically outperformed D-Pd!”
“EHA 2026 plenary session MonumenTAL-3: Tal-Dara and Tal-Dara Pom both beat Dara-Pd in terms of PFS and OS. This is despite D-Pd doing the best it ever has (mPFS > 2 yrs). BsAbs, both BCMA and GPRC5D, are here to stay in earlier lines for myeloma!”
“EHA 2026 MonumenTAL-3: Tal has real tongue/skin/cerebellar AEs, but what it doesn’t have is huge infection risk. Despite much longer time on Tx, fewer Gr3+ infections on tal-dara than Dara-Pd GPRC5D doesn’t hit normal plasma cells, and #downwithdex in Tal-D(P) helps too!”
“EHA 2026 common dogma in myeloma (I’m guilty too) getting broken by MonumenTAL-3. Weight loss overall common (then stabilized), but not more common in thin patients.
We used to say that tal less advisable in underweight/thin patients given weight loss risk – not true there.”
Other articles featuring Rahul Banerjee on OncoDaily.
